132 related articles for article (PubMed ID: 19947927)
1. A mutation in beta-tubulin and a sustained dependence on androgen receptor signalling in a newly established docetaxel-resistant prostate cancer cell line.
Hara T; Ushio K; Nishiwaki M; Kouno J; Araki H; Hikichi Y; Hattori M; Imai Y; Yamaoka M
Cell Biol Int; 2010 Jan; 34(2):177-84. PubMed ID: 19947927
[TBL] [Abstract][Full Text] [Related]
2. Interaction between docetaxel resistance and castration resistance in prostate cancer: implications of Twist1, YB-1, and androgen receptor.
Shiota M; Kashiwagi E; Yokomizo A; Takeuchi A; Dejima T; Song Y; Tatsugami K; Inokuchi J; Uchiumi T; Naito S
Prostate; 2013 Sep; 73(12):1336-44. PubMed ID: 23775496
[TBL] [Abstract][Full Text] [Related]
3. Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy.
Sowery RD; Hadaschik BA; So AI; Zoubeidi A; Fazli L; Hurtado-Coll A; Gleave ME
BJU Int; 2008 Aug; 102(3):389-97. PubMed ID: 18336596
[TBL] [Abstract][Full Text] [Related]
4. Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer.
Zhu ML; Horbinski CM; Garzotto M; Qian DZ; Beer TM; Kyprianou N
Cancer Res; 2010 Oct; 70(20):7992-8002. PubMed ID: 20807808
[TBL] [Abstract][Full Text] [Related]
5. Downmodulation of Bcl-2 sensitizes metastatic LNCaP-LN3 cells to undergo apoptosis via the intrinsic pathway.
Song R; Harris LD; Pettaway CA
Prostate; 2010 May; 70(6):571-83. PubMed ID: 19938012
[TBL] [Abstract][Full Text] [Related]
6. Docetaxel maintains its cytotoxic activity under hypoxic conditions in prostate cancer cells.
Forde JC; Perry AS; Brennan K; Martin LM; Lawler MP; Lynch TH; Hollywood D; Marignol L
Urol Oncol; 2012; 30(6):912-9. PubMed ID: 21176881
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological targeting of constitutively active truncated androgen receptor by nigericin and suppression of hormone-refractory prostate cancer cell growth.
Mashima T; Okabe S; Seimiya H
Mol Pharmacol; 2010 Nov; 78(5):846-54. PubMed ID: 20709811
[TBL] [Abstract][Full Text] [Related]
8. The use of LC-MS to identify differentially expressed proteins in docetaxel-resistant prostate cancer cell lines.
O'Connell K; Prencipe M; O'Neill A; Corcoran C; Rani S; Henry M; Dowling P; Meleady P; O'Driscoll L; Watson W; O'Connor R
Proteomics; 2012 Jul; 12(13):2115-26. PubMed ID: 22623417
[TBL] [Abstract][Full Text] [Related]
9. Melanoma cell sensitivity to Docetaxel-induced apoptosis is determined by class III beta-tubulin levels.
Mhaidat NM; Thorne RF; de Bock CE; Zhang XD; Hersey P
FEBS Lett; 2008 Jan; 582(2):267-72. PubMed ID: 18086570
[TBL] [Abstract][Full Text] [Related]
10. Toll-like receptor 4 ligation confers chemoresistance to docetaxel on PC-3 human prostate cancer cells.
Zhang Y; Wang Y; Yuan J; Qin W; Liu F; Wang F; Zhang G; Yang X
Cell Biol Toxicol; 2012 Aug; 28(4):269-77. PubMed ID: 22648782
[TBL] [Abstract][Full Text] [Related]
11. Peroxiredoxin 2 in the nucleus and cytoplasm distinctly regulates androgen receptor activity in prostate cancer cells.
Shiota M; Yokomizo A; Kashiwagi E; Takeuchi A; Fujimoto N; Uchiumi T; Naito S
Free Radic Biol Med; 2011 Jul; 51(1):78-87. PubMed ID: 21539911
[TBL] [Abstract][Full Text] [Related]
12. Androgen receptor signalling impairs docetaxel efficacy in castration-resistant prostate cancer.
Mout L; Moll JM; Chen M; de Morrée ES; de Ridder CMA; Gibson A; Stuurman D; Aghai A; Erkens-Schulze S; Mathijssen RHJ; Sparreboom A; de Wit R; Lolkema MP; van Weerden WM
Br J Cancer; 2020 Dec; 123(12):1715-1719. PubMed ID: 32989230
[TBL] [Abstract][Full Text] [Related]
13. Prostate cancer cells increase androgen sensitivity by increase in nuclear androgen receptor and androgen receptor coactivators; a possible mechanism of hormone-resistance of prostate cancer cells.
Fujimoto N; Miyamoto H; Mizokami A; Harada S; Nomura M; Ueta Y; Sasaguri T; Matsumoto T
Cancer Invest; 2007 Feb; 25(1):32-7. PubMed ID: 17364555
[TBL] [Abstract][Full Text] [Related]
14. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.
Hara T; Miyazaki J; Araki H; Yamaoka M; Kanzaki N; Kusaka M; Miyamoto M
Cancer Res; 2003 Jan; 63(1):149-53. PubMed ID: 12517791
[TBL] [Abstract][Full Text] [Related]
15. Enhanced androgen receptor signaling correlates with the androgen-refractory growth in a newly established MDA PCa 2b-hr human prostate cancer cell subline.
Hara T; Nakamura K; Araki H; Kusaka M; Yamaoka M
Cancer Res; 2003 Sep; 63(17):5622-8. PubMed ID: 14500404
[TBL] [Abstract][Full Text] [Related]
16. Development of an androgen-deprivation induced and androgen suppressed human prostate cancer cell line.
Lee SO; Dutt SS; Nadiminty N; Pinder E; Liao H; Gao AC
Prostate; 2007 Sep; 67(12):1293-300. PubMed ID: 17626246
[TBL] [Abstract][Full Text] [Related]
17. Increased expression of activated endothelial nitric oxide synthase contributes to antiandrogen resistance in prostate cancer cells by suppressing androgen receptor transactivation.
Yu S; Jia L; Zhang Y; Wu D; Xu Z; Ng CF; To KK; Huang Y; Chan FL
Cancer Lett; 2013 Jan; 328(1):83-94. PubMed ID: 22995070
[TBL] [Abstract][Full Text] [Related]
18. TGF-beta signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells.
Zhu ML; Partin JV; Bruckheimer EM; Strup SE; Kyprianou N
Prostate; 2008 Feb; 68(3):287-95. PubMed ID: 18163430
[TBL] [Abstract][Full Text] [Related]
19. EGFR mediates docetaxel resistance in human castration-resistant prostate cancer through the Akt-dependent expression of ABCB1 (MDR1).
Hour TC; Chung SD; Kang WY; Lin YC; Chuang SJ; Huang AM; Wu WJ; Huang SP; Huang CY; Pu YS
Arch Toxicol; 2015 Apr; 89(4):591-605. PubMed ID: 24888374
[TBL] [Abstract][Full Text] [Related]
20. Resistance to docetaxel-induced apoptosis in prostate cancer cells by p38/p53/p21 signaling.
Gan L; Wang J; Xu H; Yang X
Prostate; 2011 Aug; 71(11):1158-66. PubMed ID: 21656826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
